RxDoctor Payments DataLook up a doctor →

David Backstedt, MD

Gastroenterology · Little Rock, ARNPI 1245587203

Payments from drug & device makers

$16,023in general payments, 2019–2025

Across 919 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$783
  • Bristol Myers Squibb$538
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$15,65798%
  • Education$3662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,023 in reported general payments places this provider in the 80th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$160,650
Medicare patients
379
Services billed
3,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab23$211,414
CreonLipase/Protease/Amylase24$64,675
LinzessLinaclotide74$57,838
ClenpiqSod Picosulf/Mag Ox/Citric Ac32$5,416
Mesalamine34$5,147
Pantoprazole Sodium423$4,098
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,736
Colestipol Hcl23$2,023
Sucralfate55$1,924
Omeprazole92$992
Famotidine169$919
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl33$514
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$467
Esomeprazole Magnesium19$334
Dicyclomine Hcl17$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$1,308$211,41423 claims
AbbVieCreon, Linzess$6,556$122,51498 claims
Ferring Pharmaceuticals Inc.Clenpiq$56$5,41632 claims
Braintree Laboratories, Inc.Sutab$50$3,73623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →